GMP Certification Extended for Cobra Biologics
PTSM: Pharmaceutical Technology Sourcing and Management
Cobra Biologics' GMP Compliance Certification has been extended to include QC testing.
Cobra Biologics, an international CMO of biologics andpharmaceuticals, reported that its GMP Compliance Certification has been extended to include QC testing and release of customers’ registered products for in-market supply.
Following an inspection at the company’s center of excellence for mammalian antibody and recombinant protein production in Södertälje, Sweden, the the Läkemedelsverket (Medical Products Agency) has considered that the facility complies with the principles and guidelines of GMP in the Commission Directive 2003/94/EC for Human Medicinal, and Investigational Medicinal, Products.
This improved certification for biological medicinal products includes the manufacturing of active substances by culture of mammalian cells, the storage of both mammalian and microbial cell banks, the release testing of protein for clinical trials, and the QC testing of registered products.
Source: Cobra Biologics
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
